Research Article

Spermatogenesis Associated 4 Promotes Sertoli Cell Proliferation Modulated Negatively by Regulatory Factor X1

  • Junjun Jiang,

    Affiliation: MOE Key Laboratory of Protein Sciences, Department of Pharmacology, School of Medicine, Tsinghua University, Beijing, China

  • Nannan Zhang,

    Affiliation: MOE Key Laboratory of Protein Sciences, Department of Pharmacology, School of Medicine, Tsinghua University, Beijing, China

  • Hiroshi Shiba,

    Affiliations: MOE Key Laboratory of Protein Sciences, Department of Pharmacology, School of Medicine, Tsinghua University, Beijing, China, Department of Bioinformatics, Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, Tokyo, Japan

  • Liyuan Li,

    Affiliation: MOE Key Laboratory of Protein Sciences, Department of Pharmacology, School of Medicine, Tsinghua University, Beijing, China

  • Zhao Wang mail

    Affiliation: MOE Key Laboratory of Protein Sciences, Department of Pharmacology, School of Medicine, Tsinghua University, Beijing, China

  • Published: October 11, 2013
  • DOI: 10.1371/journal.pone.0075933


Spermatogenesis associated 4 (Spata4), a testis-specific and CpG island associated gene, is involved in regulating cell proliferation, differentiation and apoptosis. To obtain insight into the role of Spata4 in cell cycling control, we characterized the promoter region of Spata4 and investigated its transcriptional regulation mechanism. The Spata4 promoter is unidirectional transcribed and possesses multiple transcription start sites. Moreover, we present evidence that regulatory factor X1 (RFX1) could bind the typical 14-bp cis-elements of Spata4 promoter, modulate transcriptional activity and endogenous expression of Spata4, and further regulate the proliferation of Sertoli cells. Overexpression of RFX1 was shown to down-regulate both the promoter activity and mRNA expression of Spata4, whereas knockdown of RFX1 demonstrated the opposite effects. Our studies provide insight into Spata4 gene regulation and imply the potential role of RFX1 in growth of Sertoli cells. RFX1 may have negative effect on cell proliferation of Sertoli cells via modulating Spata4 expression levels by binding the conserved 14-bp cis-elements of Spata4 promoter.


Spermatogenesis associated 4 (Spata4) was initially identified in human testes and plays an important role in cryptorchidism development [1]. All of human, mouse and rat Spata4 genes have specifically high expression in testis, and among numerous genes that expressed in testis, only minority are testis specific genes [2][5]. Therefore, it was proposed that Spata4 participates in the spermatogenesis process [1], and may function during adolescence and maintain spermatogenesis ability, as transcript expression profiles indicated [1], [6]. In addition, recent studies indicate that Spata4 modulates cell growth, proliferation and differentiation in various cell types [1], [7], [8]. Sertoli cells produce essential factors for germ cell development and modulate male fertility [9]. And these factors are of great importance in the process of spermatogenesis [10], [11]. Clearly, the number and function of Sertoli cells determine testicular size, germ cell numbers and spermatozoa output [12]. Thus, Sertoli cell growth and proliferation may contribute to maintaining the normal physiological functions of male reproductive system.

CpG islands are often linked to promoter regions of genes [13]. The accepted definition of CpG island is regions of DNA longer than 200 bp, with a guanine/cytosine content above 50% and an ratio of observed to expected CpG presence above 0.6 [14]. The human, mouse and rat Spata4 genes showed excellent similarity of the promoter regions, especially a highly conserved region around the start codon between human and mouse Spata4 genes [6], and the CpG islands of these species also have a high similarity with each other, suggesting that Spata4 genes of these species may have some common transcription factors.

The RFX (regulatory factor for X-box) family of transcription factors consists of seven members in mammals and shares a highly conserved DNA-binding domain (DBD) [15], [16]. Besides the central located DBD domain, a conserved C-terminal region exists in RFX1 protein [17], mediating the dimerization and transcriptional repression of winged-helix RFX1 protein. RFX1 is involved in transcriptional regulation of a variety of viral and cellular genes, possesses both transcription activation and repression properties [18]. RFX1 was implicated in positive regulation of transcription from enhancer of hepatitis virus (HBV) [17] and MHC class II genes [19], [20], and negative effect was observed in transcriptional regulation of cellular genes including c-myc [21], [22], collagen α2 [23], [24], proliferating cell nuclear antigen (PCNA) [25], inhibitor of DNA binding 2 (Id2) [26], and fibroblast growth factor 1 (FGF1) [27][29]. Nevertheless, the regulatory targets of RFX1 are still not fully understood. RFX1 is expressed in various tissues. Moreover, RFX1 is prominent both in the somatic Sertoli cells of seminiferous tubules and also detected in early haploid germ cells [30], which suggested a possible role of RFX1 in male reproductive system.

Although the function of Spata4 is partially uncovered, the transcriptional regulatory mechanism of Spata4 remains to be clarified. In this study, we presented evidence that expression of Spata4 could be modulated by RFX1, which binds to the conserved 14-bp cis-elements of Spata4 promoter region. Overexpression of RFX1 could down-regulate Spata4 expression, whereas RNAi knockdown of RFX1 demonstrated the opposite effects. Moreover, RFX1 is involved in Spata4 mediated Sertoli cell growth. Our findings provide insights into Spata4 gene regulation and suggest the possible role of the RFX1, the negative transcriptional regulator of spata4, in Sertoli cell growth.


Identification and characterization of the mouse Spata4 promoter region

The mouse Spata4 gene locates on chromosome 8 B3.1 and consists of 6 exons (Figure 1A). The mouse Spata4 promoter contains a CpG island approximately 400-bp-long (Figure 1B) with GC % = 54% and ObsCpG/ExpCpG = 0.604, which comply with the accepted definition of CpG island [14]. To identify the promoter region of mouse Spata4, we first determined its transcription start site using the 5′-rapid amplification of cDNA ends method (5′-RACE). The Spata4 promoter contains dispersed transcription start sites located within a 90 bp region (Figure 1C). Transcription of Spata4 initiates with a purine at +1 at a frequency of 98% and with a pyrimidine-purine dinucleotide at position −1, +1 at a frequency of 88%, which is consistent with previous studies that RNA polymerase II-mediated transcription initiation in mammals is preferentially initiated at a pyrimidine-purine dinucleotide at position −1, +1 [31].


Figure 1. Structure of the mouse Spata4 gene and identification of the promoter region.

(A) Exon-intron structure of the Spata4 gene (1–9318) and mRNA (1–1057) as deduced by MGAlignIt using accession numbers NC_000074.5 and NM_133711.3, respectively. The colored boxes indicate the different exons. The top series of gray colored bars corresponds to individual exons drawn according to their size and position within the genomic sequence. Intron phases (0, 1 or 2) and exon borders are indicated on the bottom series of blue colored bars. (B) Mouse Spata4 promoter contains a CpG island with a length of approximately 400 bp. (C) The transcription start sites of mouse Spata4 gene. The frequency of transcription initiation from different sites is shown. The Spata4 promoter contains dispersed transcription start sites located within a 90 bp region. The first transcription start site is underlined. (D) Reporter activity assay of serially deleted promoter constructs containing different lengths of the 5′-flanking sequence of mouse Spata4 gene. The plasmids were transiently transfected into TM4 cells, and the reporter activity was analyzed 18 h after transfection. Gray bar, reverse promoter sequences; Black bar, forward promoter sequences. The values are shown as relative ratio to that of pGL4.17 control vector.


Searching the mouse Spata4 promoter showed no TATA box, initiator (Inr) or other typical core promoter elements around the transcription start sites. To determine the region that is essential for Spata4 transcription, we serially truncated the 5′-flanking region of the Spata4 promoter and analyzed its transcriptional activity through luciferase reporter assays. Deletion of the 5′-flanking region of the Spata4 promoter from −2819 to −131 retained its transcriptional activity, while further deletion to −32 abolished its transcriptional activity. Therefore, the region between −131 and +128 showed basal transcriptional activity (Figure 1D). Besides, the Spata4 promoter constructs showed little reverse transcription activity, indicating that the Spata4 promoter is unidirectional transcribed (Figure 1D).

Spata4 promoter contains a functional RFX1 binding site

Bioinformatics analysis through combination of Mulan and multi-TF scanning [32], [33] showed that the Spata4 promoter contains conserved binging sites of several transcription factors, including c-jun (key component of AP-1 complex), RREB1, HSF1, SP1 and RFX1 (Figure 2A). To address which factor could regulate Spata4 promoter activity, we serially deleted their binding sites from the −1425/+128 reporter construct. Deletion of the RFX1 binding site resulted in 4.2-fold increase of luciferase activity, while deletion of SP1 binding site decreased the luciferase activity by 0.67-fold. Deletion of AP1, RREB1 and HSF1 binding sites had little effect (Figure 2B), compared to the luciferase activity of −1425/+128 construct, respectively. These results indicate that RFX1 is a negative modulator of mouse Spata4 promoter and SP1 binding sites which locate between −131, −32 might be essential for the basal transcriptional activity of Spata4.


Figure 2. The Spata4 promoter contains a functional RFX1 binding site.

(A) Nucleotide sequences of the 5′-flanking region of the Mm/hg/rn Spata4 genes. The 5′-flanking sequences are numbered with respect to the transcription start site, Mulan combined with multiTF ( scanning revealed several conserved potential binding sites of different transcription factors. (B) Effect of deletion mutants on the relative luciferase activity of the Spata4 promoter region. TM4 cells were co-transfected with the −1425/+128 Spata4 promoter construct and each deletion mutant. The results are the means ± S.E.M. of three independent experiments performed in triplicate. ***P<0.001.


Deletion of RFX1 binding site revealed markedly up-regulation of Spata4 promoter activity, indicating that RFX1 may function as a significant transcription repressor of Spata4. The RFX1 binding sites in human, rat and mouse Spata4 promoters are highly conserved, and have high similarity with the consensus and other published RFX binding sequences (Figure 3A). Chromatin immunoprecipitation assays using two different RFX1 antibodies showed that RFX1 binds to the mouse Spata4 promoter in cultured cells. In addition, the sequences containing the GAPDH promoter are not precipitated by RFX1 antibodies (Figure 3B). These results indicated that the RFX1 binding site in the Spata4 promoter is functional.


Figure 3. RFX1 binds to the Spata4 promoter through its DNA binding domain.

(A) Alignment of the conserved 14-bp sequences of human, rat and mouse Spata4 promoter with other RFX1 binding sequences shows high similarity to the RFX1 consensus binding sites. (B) Chromatin immunoprecipitation assay confirm that RFX1 could bind the conserved 14-bp sequence in mouse Sertoli cells. (C) DNA binding domain is essential for the binding of RFX1 to the conserved sequence of Spata4 promoter. Vector, pcDNA3.1 plasmid; WT-RFX1, pcDNA3.1-RFX1 plasmid; ΔDBD-RFX1, pcDNA3.1-RFX1 plasmid with deletion of the sequences encoding the DNA binding domain. **P<0.01. ***P<0.001.


Then, we constructed a mutant of mouse RFX1 protein which lacks the DNA-binding domain to further confirm the functional binding of RFX1 to the Spata4 promoter. Deletion of the DNA-binding domain abolished the regulation of Spata4 promoter activity by RFX1, demonstrating that the DNA-binding domain is essential for the binding of RFX1 to the Spata4 promoter (Figure 3C).

RFX1 regulates endogenous Spata4 expression in TM4 Sertoli cells

Spata4 is localized in the cytoplasm of TM4 cells (Figure S1 A). The mRNA level of Spata4 is dramatically increased on postnatal days 15 in mouse testes (Figure S1 B). Furthermore, the expression of Spata4 is abundant in primary Sertoli cells harvested from mouse testis (Figure S1 C). To investigate whether RFX1 regulates endogenous Spata4 expression, we transiently overexpressed different amounts of RFX1 in TM4 cells and detected its effect on the promoter activity and the mRNA levels of Spata4. Overexpression of RFX1 was confirmed by western blotting and immuno-fluorescent assay (Figure 4A). Not only the promoter activity but also the mRNA level of Spata4 was significantly decreased by RFX1 in a dose dependent manner (Figure 4 B and C).


Figure 4. RFX1 regulates Spata4 mRNA expression in mouse Sertoli cells.

After transient transfection of pcDNA3.1-RFX1 for 36 h, the overexpressed RFX1 protein was detected by immunocytochemistry staining and Western blot (A), overexpression of RFX1 was shown to down-regulate the promoter activity (B) and Spata4 mRNA expression (C) and in a dose-dependent manner. The Spata4 mRNA expression was analyzed by quantitative PCR and normalized to GAPDH. **P<0.01. ***P<0.001.


Next, RFX1 expression was knocked down by RNA interfere in TM4 cells (Figure 5 A and B). The mRNA level of Spata4 was significantly up-regulated by RFX1 siRNA interference (Figure 5C). In addition, endogenous Spata4 gene expression could be markedly increased by RFX1 knockdown in a time-dependent manner (Figure 5 D and E).


Figure 5. Knockdown of RFX1 could up-regulate endogenous Spata4 expression.

Treatment of mouse RFX1-RNAi-I, -II and -III for 48 h could efficiently knock down the endogenous RFX1 expression (A, B). (C) Spata4 mRNA expression level was elevated upon RFX1 knockdown. Control, cells treated with nonspecific siRNA. (D) RFX1 mRNA expression level was decreased by RFX1-RNAi-III treatment. (E) Spata4 mRNA expression level was significantly elevated by RFX1-RNAi-III treatment in a time-dependent manner. *P<0.05. ***P<0.001.


RFX1 may affect proliferation of Sertoli cells through regulating Spata4 expression

Cell proliferation is closely linked to cell cycling, and cell cycle arrest can lead to suppression of proliferation rate. Exogenous expression of Spata4 in MCF7 cells significantly accelerates cell growth by traversing the S-phase and entering the G2-phase [8]. Meanwhile, stable overexpression of Spata4 could also promote Sertoli cell cycling; thereby improve Sertoli cell proliferation (Figure S2 A). Knockdown of RFX1 increased the expression of Spata4 protein in TM4 cells and the cell growth rate (Figure 6 A and C, Figure S2 B), while overexpression of RFX1 could decrease the cell growth rate (Figure 6B, Figure S2 B), suggesting that RFX1 affects the proliferation of Sertoli cells in vitro and that the inhibitory effect was consistent with its regulatory effect on Spata4. The regulation of Spata4 by RFX1 and their roles in Sertoli cell proliferation are illustrated in Figure 6D. Taken together, these results indicated that endogenous expression of Spata4 is important for Sertoli cell growth.


Figure 6. RFX1 is involved in Spata4 mediated cell growth.

(A) The protein level of RFX1 was decreased while Spata4 was increased in a time-dependent manner with RFX1-siRNA transfection in TM4 cells. (B) RFX1 was transiently overexpressed in TM4 cells for 0, 24 and 48 h, (C) TM4 cells were treated with Nonspecific-siRNA (50 nM) and RFX1-siRNA (50 nM) for 0, 24 and 48 h, then cell growth was measured by CCK-8 assay. Data are shown as means ± S.E.M., P<0.05. (D) The regulation of Spata4 by RFX1 and their roles in Sertoli cell proliferation are illustrated. RFX1 dimerizes in the nucleus, then the dimer binds to the concensus 14-bp elements in Spata4 gene promoter region via the DBD domain and inhibits Spata4 gene transcription. Down-regulated Spata4 then decreases the growth rate of Seroli cells.



Spata4, conserved in male reproductive system, is important in several biological processes, including cell growth, proliferation and differentiation. However, the transcriptional regulation of Spata4 was not thoroughly investigated. Here we identified the promoter region of Spata4 and studied the mechanism of its transcriptional regulation. The mouse Spata4 promoter contains a CpG island and possesses dispersed transcription start sites, whereas no core promoter elements, such as the TATA box, Initiator (Inr) and Downstream Promoter Element (DPE) were found around the transcription start sites of Spata4.

Bioinformatics prediction revealed that the Spata4 promoter contains potential binding sites of several transcription factors, including AP1, SP1, RFX1, RREB1 and HSF1. Luciferase reporter assays showed that the region between −131 and +128 of the Spata4 promoter accounts for its basal transcriptional activity. SP1, which binds to the consensus sequence of CCCGCCC that exists in many CpG island with high GC content, may involve in the transcription initiation of the CpG island promoters [34]. Deletion of the SP1 consensus binding sites located between −131, −32 markedly decreased the promoter activity, suggesting that SP1 may function as an important factor in recruiting transcription apparatus to Spata4 promoter and regulating the transcription activity of Spata4.

RFX1, a dual function transcription regulator, has both transcriptional activation and repression properties depending on the promoter context [18]. Mutation of the RFX1 binding site increased the transcriptional activity of the Spata4 promoter significantly. Furthermore, overexpression of RFX1 reduced both the Spata4 promoter activity and the mRNA levels of Spata4, while knockdown of RFX1 had the opposite effects. Consequently, RFX1 was a remarkable negative regulator of Spata4 expression.

The RFX proteins bind to DNA as dimers and RFX1-4 can form either heterodimers or homodimers [17], [35][37], resulting in the RFX complex possesses similar specificities of binding sites. RFX1 is ubiquitously detected in various tissues with little variability [17]. RFX2 was the most prominent RFX mRNA detected in mouse testis. RFX3 and RFX4 were prevalent in testis [17], yet the RFX4 splice variants in testis are defective due to lack of the transcriptional activation region or the DNA-binding domain [35], [38]. RFX1, RFX2 and RFX3, share high similarity and have identical binding site specificities and the ability of cross-dimerization. The interaction among RFX1, RFX2 and RFX3 and their roles in regulation of Spata4 promoter activity are therefore worthy of further investigation. Of particular interest, it remains to be uncovered whether other testis specific co-activators are required for RFX1 or other RFX proteins.

In conclusion, we identified the transcription factor RFX1 as a novel negative regulator of Spata4 gene promoter activity, and provided insight into the regulation of Spata4 gene. Given the specificity of gene expression pattern of Spata4 in testis, identification of such a transcription factor brings us closer to the understanding of Spata4 dependent processes including spermatogenesis and cryptorchidism development, and also helps to uncover more biological functions of Spata4.

Materials and Methods

Ethics statement

The Animal Protocol (AP) was approved by the Institutional Animal Care and Use Committee of Tsinghua University (IACUCTHU) (AP#: 11-WZ1) with animal care performed strictly according to established institutional guidelines. All surgery was performed under pentobarbital anesthesia, and all efforts were made to minimize suffering.

Plasmid constructs

The mouse genomic sequence of the 5′-flanking region of the Spata4 gene including the transcription start site was obtained from GenBank (accession no. NC_000074). DNA extracted from the whole blood cells from C57/BL6 mice with TIANamp Blood DNA Kit (TIANGEN Biotech., Beijing, China) was used as the template. Different truncations of mouse Spata4 promoter were cloned into the Kpn I and Xho I restriction sites of the pGL4.17 vector (Promega, Madison, WI). The expression plasmid for wild-type RFX1 and was constructed by cloning the corresponding sequence into Kpn I and Xho I restriction sites of pCDNA3.1 myc-His A vector (Invitrogen, Carlsbad, CA). Mutation PCR reactions were performed with PrimSTAR HS polymerase (Takara Bio Inc., Shiga, Japan), 5′-end of the purified PCR products was kinated and ligated using DNA Kination Kit (Takara) referring to the manufacturer's protocol. The primers used during the plasmid construction are shown in Table S1 and S2.

Cell culture

Mouse Sertoli cell TM4 were cultured in DMEM/F-12 (Thermo Scientific HyClone, Logan, UT), supplemented with 10% fetal bovine serum (Thermo Scientific HyClone), 100 U/ml penicillin and 100 μg/ml streptomycin, at 37°C in a humidified atmosphere containing 5% CO2.

5′ Rapid amplification cDNA ends

Rapid Amplification of cDNA Ends (RACE) was performed using the SMARTTM RECE cDNA Amplification kit (Clontech, Shiga, Japan) following manufacturers' protocols, to determine the transcription start sites of mouse Spata4. Ploy A+ RNA was purified from testis total RNA of 2-months-old C57 BL/6J mice by OligotexTM mRNA Purification system (Qiagen Inc., Valencia, CA). 5′-RACE-Ready cDNA was synthesized using 5′-CDS (Clontech) primer and SMART II A oligo (Clontech). 5′ RACE PCR was performed with 5′-RACE UPM (Clontech) and Spata4 specific primer: 5′-GCAGGACAGAACGACTCAGGCGGG-3′, followed by a nested PCR using 5′- nested UPM (Clontech) and a nested Spata4-specific primer: 5′- TCCTGCGGGAACTGCTGGTGGTGTAG-3′. As a negative control, 5′-RACE Ready cDNA was amplified with 5′-RACE UPM only. The nested PCR products were then sub-cloned into pMD19-T vector (Takara) and a total of 60 positive clones were sequenced.

Bioinformatics analysis

Mulan (Multiple-sequence local alignment) analysis was carried out comparing the genomic sequences of about 2000 bp upstream Spata4 first exon of human, mouse and rat, combined multiTF ( scanning for conserved transcription factor binding sites (TFBS).

Cell transfection and luciferase assay

TM4 cells (1×105 cells/ml) were seeded in 24-well plates in antibiotic-free culture medium the day before transfection. Each well of cells were transiently transfected with 0.8 μg of Spata4 reporter plasmids and 0.08 μg Renilla reporter plasmid (phRL-TK, Promega) as an internal control using LipofectamineTM 2000 (Invitrogen). Alternatively, cells were co-transfected with 0.4 μg Spata4 reporter plasmids, 0.04 μg phRL-TK plasmid and 0.4 μg total amounts of pcDNA3.1 and RFX1 expressing plasmids in a dose dependent manner. Cells were incubated with the DNA-LipofectamineTM 2000 complex for 6 h, then washed gently with phosphate-buffered saline (PBS) buffer, and cultured in fresh serum-supplemented media for an additional 18 h. Cell lysates were collected and used for measurement of the relative promoter activity of each fragment with the dual luciferase reporter assay system (Promega). pGL4.17 [luc2] vector contains no promoter region was used as a control.

RNAi knockdown experiment

Small interfering RNA knockdown experiments were performed with synthesized siRNA (Genechem, Shanghai, China). Target sequences of RFX1 for siRNA are shown as follow: RFX1-siRNA-I, 5′-AGAACACTGCACAGATCAA-3′; RFX1-siRNA-II, 5′-ACTGTGACAATGTGCTGTA-3′; RFX1-siRNA-III, 5′-TCATGGTAAACCTGCAGTT-3′. Non-specific siRNA was synthesized as forward: 5′- UUCUCCGAACGUGUCACGUtt-3′, reverse: 5′-ACGUGACACGUUCGGAGAAtt-3′. TM4 cells were used in RNAi knockdown experiments. Cells were transfected with the small interfering RNA using Lipofectamine RNAiMAX transfection reagent (Invitrogen) according to the manufacturer's instructions. The three different siRNA (I, II, and III) against RFX1 were tested, and RFX1-siRNA-III were used for further RNAi knockdown experiments.

Chromatin Immunoprecipitation (ChIP) Assay

ChIP was performed using the Magnetic Chromatin Immunoprecipitation Kit (Active Motif, Carlsbad, CA) as described in the manufacturer's protocol. Briefly, TM4 cells were washed once with phosphate buffered saline and then fixed in culture medium containing 1% formaldehyde at room temperature for 10 min. Cells were then collected and lysed to release the nucleus. The nucleus was digested with the enzyme mix at 37°C for 10 min to shear the chromatin into small segments. 2 μg of RFX1 (I-19) antibodies (Santa Cruz Biotechnology, Santa Cruz, CA), 2 μg of RFX1 (D-19) antibodies (Santa Cruz), or a negative control IgG (Abcam, Cambridge, UK) were used for immunoprecipitation of the sheared chromatin at 4°C for 4 h. The pulled-down chromatin was washed, reverse cross-linked and purified. PCR primers for mouse Spata4 promoter were forward: 5′-CACAGAGCCTTCTTGGAGG-3′ and reverse: 5′-GGGAACTGCTGGTGGTGTA-3′. PCR primers for mouse GAPDH promoter were forward: 5′-GCCCTTGAGCTAGGACTGGAT-3′ and reverse: 5′-CCTGGCACTGCACAAGAAGAT-3′.

Quantitative real-time polymerase chain reaction (RT-qPCR)

Total RNA was extracted from TM4 cells using Trizol reagent (Invitrogen) according to the manufacturer's protocol. cDNA was transcribed with RevaTra Ace reverse transcriptase (Toyobo, Osaka, Japan) using oligo (dT)20 as primers. Each cDNA transcribed from 0.8 μg RNA was subsequently used for RT-qPCR analysis with SYBR Green Real-time PCR Mater Mix (Toyobo) in CFX96 Real-Time PCR Detection Systems (Bio-Rad, Hercules, CA). PCR primers for mouse Spata4 were forward: 5′-CAGATACAAGTCAAGAGGTTC-3′ and reverse: 5′-GTGTTCTCACAAGGATTTCCAC -3′. PCR primers for mouse RFX1 were forward: 5′-TGCTGCCCCTGCACCCTCACA-3′ and reverse: 5′-GGTGGGAACACCGGTCTGGCTT-3′. PCR primers for mouse GAPDH were forward: 5′-CATGGCCTTCCGTGTTCCTA-3′ and reverse: 5′-CCTGCTTCACCACCTTCTTGAT-3′. All the primers are intron-spanning. The specificity of primers was confirmed by the melting curves which performed on the amplified products. The thermal cycling conditions were as follows: initial denaturation at 95°C for 10 min, followed by 40 cycles of denaturing at 95°C for 15 s, annealing at 60°C for 30 s and extension at 72°C for 30 s.

Western blotting

Cells were collected and lysed with the cell lysis buffer (Beyotime, Shanghai, China). Alternatively, nuclear protein was isolated with the Nuclear and Cytoplasmic Protein Extraction Kit (Beyotime). Protein concentrations were determined using the BCA Protein Assay Kit (Thermo Scientific). Protein samples were separated by electrophoresis through SDS-PAGE gels and transferred to polyvinylidene difluoride membranes (Millipore, Schwalbach, Germany). The membranes were blocked at room temperature for 1.5 h in Tris-buffered saline containing 0.05% Tween 20 with 5% non-fat dry milk. The membranes were then incubated with primary antibodies specific for RFX1 (1:500; Santa Cruz), Spata4 (1:1000; prepared by our laboratory), GAPDH (1:1000; Cwbiotech, Beijing, China) or β-tublin (1:1000; Cwbiotech) at 4°C overnight, followed by an incubation with horseradish peroxidase-conjugated anti-goat IgG (1:5000; Santa Cruz) or anti-rabbit IgG (1:10000) at room temperature for 1 h. The chemiluminescence reaction was performed using ECL reagent (Thermo Scientific).

Immunofluorescence staining

TM4 cells were seeded on a 6-well dish with a density of 1×105 cells/ml and fixed with methylate-acetone (1:1) for 30 min. After blocking with 10% bovine serum albumin (BSA) for 1 hour, a primary antibody against RFX1 (1:100; Santa Cruz) was added for 2 h, followed by an anti-goat IgG conjugated with FITC (1:100; Santa Cruz) for 1 h. DAPI (0.1 mg/ml) was added to label the nucleus for 10 min. A negative control without the primary antibody was used to monitor the staining background. Images were obtained through Leica DX100 (Leica Microsystems Wetzlar GmbH, Germany).

CCK-8 assay

TM4 cells were suspended at a final concentration of 2×104 cells/ml and seeded in 96-well plates, then transiently transfected with pcDNA3.1-vector, pcDNA3.1-RFX1, non-specific siRNA, siRNA-RFX1, respectively. After incubation for the indicated time as 0, 24 and 48 h, cell growth was determined by the CCK-8 assay (Beyotime). In brief, 10 μl CCK-8 solutions were added to each well and cultures were incubated at 37°C for 2 h. The absorbance at 450 nm was measured with a Benchmark microplate reader (Bio-Rad).

Statistical analysis

The values reported in graphs are the means ± S.E.M. from three independent experiments. One-way ANOVA followed by Bonferroni multiple comparison was performed to assess the differences. A value of P<0.05 was considered statistically significant.

Supporting Information

Figure S1.

Spata4 protein localization in Sertoli cells and its expression in mouse testis. (A) Spata4 protein localization in TM4 cells via immunofluorescence. Fluorescein isothiocyanate (FITC) staining of Spata4 (green; anti-Spata4) is shown. Propidium iodide (PI) staining of cell nuclei (red), a composite image (Merge) and a negative control (Neg) are presented. Images shown were captured at 630 fold magnification via confocal laser scanning microscopy. (B) RT-qPCR analysis of mouse Spata4 expression in developing testis including day 7, day 11, day 15, day 21, day 30, day 60. As shown in the figure, expression of mouse Spata4 can be detected after the mouse is 15 days old. (C) Expression of Spata4 in mouse Sertoli cells. The mRNA levels of Spata4 in primary Sertoli cells, TM4 Sertoli cells and testes are determined by RT-PCR. Columns and bars indicate the mean ± S.E.M. of values independently repeated three times.



Figure S2.

Effect of Spata4 on cell cycle distribution and cell proliferation of TM4 Sertoli cells. (A) Confluent TM4 and TM4/Spata4 cells (1×107 cells/10 cm dish) were harvested and cell cycle distribution was determined by flow cytometry analysis. (B) RFX1 was transiently overexpressed in TM4 cells for 0, 24 and 48 h, and TM4 cells were treated with Nonspecific-siRNA (50 nM) and RFX1-siRNA (50 nM) for 0, 24 and 48 h, then total cell number were counted. Data are shown as means ± S.E.M., P<0.05.



Table S1.

PCR primers used for constructing the reporter plasmids of the mouse Spata4 promoter.



Table S2.

PCR primers used for constructing the wild-type and mutant mouse RFX1.



Author Contributions

Conceived and designed the experiments: JJ ZW. Performed the experiments: JJ NZ HS LL. Analyzed the data: JJ NZ. Wrote the paper: JJ ZW. Read and approved the final manuscript: JJ NZ HS LL ZW.


  1. 1. Liu SF, He S, Liu BW, Zhao Y, Wang Z (2004) Cloning and characterization of testis-specific spermatogenesis associated gene homologous to human SPATA4 in rat. Biol Pharm Bull 27: 1867–1870. doi: 10.1248/bpb.27.1867
  2. 2. Weitzel JM, Shiryaeva NB, Middendorff R, Balvers M, Radtke C, et al. (2003) Testis-specific expression of rat mitochondrial glycerol–3-phosphate dehydrogenase in haploid male germ cells. Biol Reprod 68: 699–707. doi: 10.1095/biolreprod.102.008540
  3. 3. Olesen C, Larsen NJ, Byskov AG, Harboe TL, Tommerup N (2001) Human FATE is a novel X-linked gene expressed in fetal and adult testis. Mol Cell Endocrinol 184: 25–32. doi: 10.1016/s0303-7207(01)00666-9
  4. 4. Ogi T, Mimura J, Hikida M, Fujimoto H, Fujii-Kuriyama Y, et al. (2001) Expression of human and mouse genes encoding polkappa: testis-specific developmental regulation and AhR-dependent inducible transcription. Genes Cells 6: 943–953. doi: 10.1046/j.1365-2443.2001.00478.x
  5. 5. Imai-Senga Y, Sun-Wada GH, Wada Y, Futai M (2002) A human gene, ATP6E1, encoding a testis-specific isoform of H (+)-ATPase subunit E. Gene. 289: 7–12. doi: 10.1016/s0378-1119(02)00542-5
  6. 6. Liu SF, Ai C, Ge ZQ, Liu HL, Liu BW, et al. (2005) Molecular cloning and bioinformatic analysis of SPATA4 gene. J Biochem Mol Biol 38: 739–747. doi: 10.5483/bmbrep.2005.38.6.739
  7. 7. Wang X, Harimoto K, Liu J, Guo J, Hinshaw S, et al. (2011) Spata4 promotes osteoblast differentiation through Erk-activated Runx2 pathway. J Bone Miner Res 26: 1964–1973. doi: 10.1002/jbmr.394
  8. 8. Liu SF, Lu GX, Liu G, Xing XW, Li LY, et al. (2004) Cloning of a full-length cDNA of human testis-specific spermatogenic cell apoptosis inhibitor TSARG2 as a candidate oncogene. Biochem Biophys Res Commun 319: 32–40. doi: 10.1016/j.bbrc.2004.04.160
  9. 9. Griswold MD (1998) The central role of Sertoli cells in spermatogenesis. Semin Cell Dev Biol 9: 411–416. doi: 10.1006/scdb.1998.0203
  10. 10. Eddy EM (2002) Male germ cell gene expression. Recent Prog Horm Res 57: 103–128. doi: 10.1210/rp.57.1.103
  11. 11. Tanaka H, Baba T (2005) Gene expression in spermiogenesis. Cell Mol Life Sci 62: 344–354. doi: 10.1007/s00018-004-4394-y
  12. 12. Orth JM, Gunsalus GL, Lamperti AA (1988) Evidence from Sertoli cell-depleted rats indicates that spermatid number in adults depends on numbers of Sertoli cells produced during perinatal development. Endocrinology 122: 787–794. doi: 10.1210/endo-122-3-787
  13. 13. Antequera F, Bird A (1993) Number of CpG islands and genes in human and mouse. Proc Natl Acad Sci U S A 90: 11995–11999. doi: 10.1073/pnas.90.24.11995
  14. 14. Gardiner-Garden M, Frommer M (1987) CpG islands in vertebrate genomes. J Mol Biol 196: 261–282. doi: 10.1016/0022-2836(87)90689-9
  15. 15. Aftab S, Semenec L, Chu JS, Chen N (2008) Identification and characterization of novel human tissue-specific RFX transcription factors. BMC Evol Biol 8: 226. doi: 10.1186/1471-2148-8-226
  16. 16. Emery P, Durand B, Mach B, Reith W (1996) RFX proteins, a novel family of DNA binding proteins conserved in the eukaryotic kingdom. Nucleic Acids Res 24: 803–807. doi: 10.1093/nar/24.5.803
  17. 17. Reith W, Ucla C, Barras E, Gaud A, Durand B, et al. (1994) RFX1, a transactivator of hepatitis B virus enhancer I, belongs to a novel family of homodimeric and heterodimeric DNA-binding proteins. Mol Cell Biol 14: 1230–1244.
  18. 18. Katan Y, Agami R, Shaul Y (1997) The transcriptional activation and repression domains of RFX1, a context-dependent regulator, can mutually neutralize their activities. Nucleic Acids Res 25: 3621–3628. doi: 10.1093/nar/25.18.3621
  19. 19. Tsang SY, Nakanishi M, Peterlin BM (1990) Mutational analysis of the DRA promoter: cis-acting sequences and trans-acting factors. Mol Cell Biol 10: 711–719.
  20. 20. Kouskoff V, Mantovani RM, Candeias SM, Dorn A, Staub A, et al. (1991) NF-X, a transcription factor implicated in MHC class II gene regulation. J Immunol 146: 3197–3204.
  21. 21. Reinhold W, Emens L, Itkes A, Blake M, Ichinose I, et al. (1995) The myc intron-binding polypeptide associates with RFX1 in vivo and binds to the major histocompatibility complex class II promoter region, to the hepatitis B virus enhancer, and to regulatory regions of several distinct viral genes. Mol Cell Biol 15: 3041–3048.
  22. 22. Chen L, Smith L, Johnson MR, Wang K, Diasio RB, et al. (2000) Activation of protein kinase C induces nuclear translocation of RFX1 and down-regulates c-myc via an intron 1 X box in undifferentiated leukemia HL-60 cells. J Biol Chem 275: 32227–32233. doi: 10.1074/jbc.m002645200
  23. 23. Sengupta PK, Ehrlich M, Smith BD (1999) A methylation-responsive MDBP/RFX site is in the first exon of the collagen alpha2(I) promoter. J Biol Chem 274: 36649–36655. doi: 10.1074/jbc.274.51.36649
  24. 24. Sengupta P, Xu Y, Wang L, Widom R, Smith BD (2005) Collagen alpha1(I) gene (COL1A1) is repressed by RFX family. J Biol Chem 280: 21004–21014. doi: 10.1074/jbc.m413191200
  25. 25. Liu M, Lee BH, Mathews MB (1999) Involvement of RFX1 protein in the regulation of the human proliferating cell nuclear antigen promoter. J Biol Chem 274: 15433–15439. doi: 10.1074/jbc.274.22.15433
  26. 26. Wang KR, Nemoto T, Yokota Y (2007) RFX1 mediates the serum-induced immediate early response of Id2 gene expression. J Biol Chem 282: 26167–26177. doi: 10.1074/jbc.m703448200
  27. 27. Alam KY, Frostholm A, Hackshaw KV, Evans JE, Rotter A, et al. (1996) Characterization of the 1B promoter of fibroblast growth factor 1 and its expression in the adult and developing mouse brain. J Biol Chem 271: 30263–30271. doi: 10.1074/jbc.271.47.30263
  28. 28. Ray SK, Yang XQ, Chiu IM (1997) Transcriptional activation of fibroblast growth factor 1.B promoter is mediated through an 18-base pair cis-acting element. J Biol Chem 272: 7546–7555. doi: 10.1074/jbc.272.11.7546
  29. 29. Hsu YC, Liao WC, Kao CY, Chiu IM (2010) Regulation of FGF1 gene promoter through transcription factor RFX1. J Biol Chem 285: 13885–13895. doi: 10.1074/jbc.m109.081463
  30. 30. Kistler WS, Horvath GC, Dasgupta A, Kistler MK (2009) Differential expression of Rfx1-4 during mouse spermatogenesis. Gene Expr Patterns 9: 515–519. doi: 10.1016/j.gep.2009.07.004
  31. 31. Carninci P, Sandelin A, Lenhard B, Katayama S, Shimokawa K, et al. (2006) Genome-wide analysis of mammalian promoter architecture and evolution. Nat Genet 38: 626–635. doi: 10.1038/ng1789
  32. 32. Loots GG, Ovcharenko I (2007) Mulan: multiple-sequence alignment to predict functional elements in genomic sequences. Methods Mol Biol 395: 237–254. doi: 10.1385/1-59745-514-8:237
  33. 33. Ovcharenko I, Loots GG, Giardine BM, Hou M, Ma J, et al. (2005) Mulan: multiple-sequence local alignment and visualization for studying function and evolution. Genome Res 15: 184–194. doi: 10.1101/gr.3007205
  34. 34. Antequera F (2003) Structure, function and evolution of CpG island promoters. Cell Mol Life Sci 60: 1647–1658. doi: 10.1007/s00018-003-3088-6
  35. 35. Morotomi-Yano K, Yano K, Saito H, Sun Z, Iwama A, et al. (2002) Human regulatory factor X 4 (RFX4) is a testis-specific dimeric DNA-binding protein that cooperates with other human RFX members. J Biol Chem 277: 836–842. doi: 10.1074/jbc.m108638200
  36. 36. Gajiwala KS, Chen H, Cornille F, Roques BP, Reith W, et al. (2000) Structure of the winged-helix protein hRFX1 reveals a new mode of DNA binding. Nature 403: 916–921. doi: 10.1038/35002634
  37. 37. Reith W, Herrero-Sanchez C, Kobr M, Silacci P, Berte C, et al. (1990) MHC class II regulatory factor RFX has a novel DNA-binding domain and a functionally independent dimerization domain. Genes Dev 4: 1528–1540. doi: 10.1101/gad.4.9.1528
  38. 38. Blackshear PJ, Graves JP, Stumpo DJ, Cobos I, Rubenstein JL, et al. (2003) Graded phenotypic response to partial and complete deficiency of a brain-specific transcript variant of the winged helix transcription factor RFX4. Development 130: 4539–4552. doi: 10.1242/dev.00661